CUMBERLAND PHARMACEUTICALS INC
For the period ended Sep 30, 2024. Filed Nov 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 8, 2024
CPIX$5.37+2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three months ended September 30, | Nine months ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net revenues | $9,085,826 | $10,085,926 | $27,432,376 | $30,199,441 |
| Costs and expenses: | ||||
| Cost of products sold | 1,323,013 | 1,765,590 | 4,609,499 | 4,536,628 |
| Selling and marketing | 4,397,480 | 4,743,142 | 12,800,469 | 13,692,535 |
| Research and development | 1,306,095 | 1,924,768 | 3,523,535 | 4,569,476 |
| General and administrative | 2,675,380 | 2,343,855 | 7,800,435 | 7,212,731 |
| Amortization | 1,078,290 | 1,175,174 | 3,288,808 | 3,563,493 |
| Total costs and expenses | 10,780,258 | 11,952,529 | 32,022,746 | 33,574,863 |
| Operating loss | (1,694,432) | (1,866,603) | (4,590,370) | (3,375,422) |
| Interest income | 69,190 | 98,603 | 227,777 | 205,854 |
| Other income | — | — | — | 2,828,871 |
| Other income - settlement | — | 475,000 | — | 475,000 |
| Other income - insurance proceeds | 237,089 | 346,800 | 237,089 | 346,800 |
| Interest expense | (137,374) | (110,081) | (382,247) | (489,069) |
| Loss before income taxes | (1,525,527) | (1,056,281) | (4,507,751) | (7,966) |
| Income tax expense | (11,442) | (6,938) | (34,327) | (20,813) |
| Net loss | (1,536,969) | (1,063,219) | (4,542,078) | (28,779) |
| Net loss (income) at subsidiary attributable to noncontrolling interests | (7,112) | 13,921 | (33,878) | 43,865 |
| Net income (loss) attributable to common shareholders | $(1,544,081) | $(1,049,298) | $(4,575,956) | $15,086 |
| Earnings (loss) per share attributable to common shareholders | ||||
| - basic | $(0.11) | $(0.07) | $(0.32) | $— |
| - diluted | $(0.11) | $(0.07) | $(0.32) | $— |
| Weighted-average shares outstanding | ||||
| - basic | 14,052,754 | 14,277,229 | 14,089,496 | 14,343,560 |
| - diluted | 14,052,754 | 14,277,229 | 14,089,496 | 14,521,600 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.